leramistat
Chronic disease with tissue damage (specific indication not disclosed)
Phase 2Active
Key Facts
Indication
Chronic disease with tissue damage (specific indication not disclosed)
Phase
Phase 2
Status
Active
Company
About Istesso
Istesso is a private, clinical-stage biotech founded in 2018, headquartered in Oxford, UK. The company is developing a groundbreaking platform of oral regenerative medicines based on mitochondrial Complex I modulators (MCMs), with a lead asset, leramistat, in Phase 2 trials. Its strategy targets a paradigm shift in chronic disease management by focusing on tissue repair and restoration of health, moving beyond symptomatic control. Istesso's pipeline has blockbuster potential across multiple age-related chronic diseases, positioning it as a leader in a nascent but highly promising therapeutic field.
View full company profile